MDM2 and plasma cell myeloma: This pilot study demonstrated for the first time in vivo protein expression of MDM2 in the bone marrow of patients with multiple myeloma, as well as the possible effect of bortezomib on the expression of this protein in the microenvironment of multiple myeloma.